GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Short Percentage of Float

ALPMF (Astellas Pharma) Short Percentage of Float


View and export this data going back to 2009. Start your Free Trial

What is Astellas Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Astellas Pharma's Short Percentage of Float

For the Drug Manufacturers - General subindustry, Astellas Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Short Percentage of Float falls into.


;
;

Astellas Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMF) » Definitions » Short Percentage of Float
Comparable Companies
TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4568 LLY JNJ ABBV OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN MRK AMGN PFE GILD XPAR:SAN BMY
Traded in Other Exchanges
ALPMY:USA 4503:Japan YPH:Germany
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Website
http://www.astellas.com
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.